EP Patent

EP1262176A1 — Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor

Assigned to Warner Lambert Co LLC · Expires 2002-12-04 · 23y expired

What this patent protects

The present invention provides a method of treating or preventing neutrophil chemotaxis. Specifically, the present invention provides a method of treating or preventing neutrophil migration by administering to a patient a MEK inhibitor. <IMAGE> <IMAGE> <IMAGE&g…

USPTO Abstract

The present invention provides a method of treating or preventing neutrophil chemotaxis. Specifically, the present invention provides a method of treating or preventing neutrophil migration by administering to a patient a MEK inhibitor. <IMAGE> <IMAGE> <IMAGE>

Drugs covered by this patent

Patent Metadata

Patent number
EP1262176A1
Jurisdiction
EP
Classification
—
Expires
2002-12-04
Drug substance claim
No
Drug product claim
No
Assignee
Warner Lambert Co LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.